A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation. METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. RESULTS: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. CONCLUSIONS: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. 75-79”
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
(1994) · Medical Entomology and Zoology · Cited by 4,156
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P. D., & Johanson, J. F. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,080
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationChronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 584
Stewart, W. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00701-7 · Cited by 492
Psychometric Validation of a Constipation Symptom Assessment Questionnaire
L. Frank, L. K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025327 · Cited by 458
The Health-Related Quality of Life and Economic Burden of Constipation
Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S. K., Dhawan, R., & Coyne, K. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00006 · Cited by 396
Research works printed but not linked: 3
- 10.1111/j.1572-0241.1999.01642.x · doi:10.1111/j.1572-0241.1999.01642.x · Paper page
- 10.1111/j.1572-0241.2002.05843.x · doi:10.1111/j.1572-0241.2002.05843.x · Paper page
- Schiller LR, 2004, Rev Gastroenterol Disord, 4, S43
Cited by
Items 201–300 of 581
Vandeplassche, L. M., Smith, Mannaert, Verhaeghe, Kerstens, & de Velde, V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s36142 · Cited by 28
Self-citationOpioid induced constipation in cancer patients: pathophysiology, diagnosis and treatment
Rumman, A., Gallinger, Z. R., & Liu, L. W. C. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2016.1131595 · Cited by 31
“patients with idiopathic, non-opioid-induced constipation [58].”
Roque, M. V., & Camilleri, M. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.30 · Cited by 27
Self-citationNovel Pharmacological Therapies for Management of Chronic Constipation
González-Martínez, M. A., Ortiz-Olvera, N. X., & Méndez-Navarro, J. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436440.05887.02 · Cited by 29
Bor, S., Kalkan, İ. H., Savarino, E. V., Rao, S. S. C., Tack, J. F., Pasricha, J., Cangemi, D. J., Schol, J., Karunaratne, T. B., Ghisa, M., et al. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14774 · Cited by 31
Pharmacologic treatment of constipation: what is new?
Pohl, D., Tutuian, R. I., & Fried, M. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.008 · Cited by 26
The association between prucalopride efficacy and constipation type
Jadav, A. M., Mcmullin, C. M., Smith, J. H. F., Chapple, K. S., & Brown, S. R. (2013) · Techniques in Coloproctology · doi:10.1007/s10151-013-1017-8 · Cited by 26
Prucalopride: a new drug for the treatment of chronic constipation
Tack, J. F. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.38 · Cited by 26
Nennstiel, S., Bajbouj, M., Schmid, R. M., & Becker, V. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-34 · Cited by 27
“It is approved in the therapy of chronic constipation in women and stimulates colonic movement [13].”
BackgroundConstipation in Parkinson's Disease
Quigley, E. M. M. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771457 · Cited by 28
Ke, M., Tack, J., Quigley, E. M. M., Zou, D., Choi, S. C., Leelakusolvong, S., Liu, A., & Kim, J. (2014) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.20.458 · Cited by 25
“Most importantly, prucalopride has been shown to be effective and well-tolerated in the treatment of CC in a number of randomized controlled clinical trials and follow-up studies lasting as long as 18 months.(9,15,17,18) Prucalopride is approved in many countries for the symptomatic treatment of CC in women, in whom l…”
Long, D. D., Armstrong, S. R., Beattie, D. T., Choi, S. K., Fatheree, P. R., Gendron, R. A. L., Genov, D. G., Goldblum, A. A., Humphrey, P. P. A., Jiang, L., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.051 · Cited by 25
A randomized controlled trial of acupuncture to treat functional constipation: design and protocol
Xu, X., Zheng, C., Zhang, M., Wang, W., & Huang, G.-Y. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-423 · Cited by 26
“Sample size calculation Sample size was determined based on a study [15] where the average defecation rate of patients with functional constipation was 2.”
MethodNew Treatments for Irritable Bowel Syndrome in Women
Adeyemo, M. A., & Chang, L. (2008) · Women s Health · doi:10.2217/17455057.4.6.605 · Cited by 30
Current management strategies and therapeutic targets in chronic constipation
Emmanuel, A. V. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10384173 · Cited by 27
“A multi-centre European study reported that 63% of refractory patients reported increased bowel frequency, reduced straining and time spent toileting.”
MethodMueller‐Lissner, S., & Wald, A. M. (2010) · Europe PMC (PubMed Central) · Cited by 25
Persistent constipation and abdominal adverse events with newer treatments for constipation
Sonu, I. S., Triadafilopoulos, G., & Gardner, J. D. (2016) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2016-000094 · Cited by 27
“…publications provided detailed descriptions of the conditions under which rescue medication was to be used, such as three consecutive days without a bowel movement, 15 18 – 21 26 28 – 31 33 37 39 whereas, other publications only mentioned use of rescue medication in passing 34 38 or not at all.”
MethodXu, X., Zhang, M., Wu, X. W., Xu, S., Wang, W., Zheng, C.-H., & Huang, G.-Y. (2020) · Current Medical Science · doi:10.1007/s11596-020-2188-y · Cited by 24
Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome
Barboza, J., Talley, N. J., & Moshiree, B. (2014) · Drugs · doi:10.1007/s40265-014-0292-7 · Cited by 24
Priem, E. K. V., Colen, I. V., Maeyer, J. H. D., & Lefebvre, R. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.020 · Cited by 25
Bead study: a novel method to measure gastrointestinal transit in mice
Reed, D. E., Pigrau, M., Lu, J., Moayyedi, P., Collins, S. M., & Berčík, P. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12442 · Cited by 24
Sun, Z., Zuo, L., Kang, J., Zhou, L., Jia, M., Li, Z., Yang, Z., Zhang, X., & Zhu, Z. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.09.006 · Cited by 28
Naumann, J., Sadaghiani, C., Alt, F., & Huber, R. (2016) · Complementary Medicine Research · doi:10.1159/000449436 · Cited by 24
“…an increase of 2.8 bowel movements per week at baseline to 4.80 after 3 weeks and 4.52 after 6 weeks, the improvement seen in the treatment group can be regarded as clinically relevant since 3 or more bowel movements a week is considered the low end of the range defining normal bowel function [31].”
BackgroundInfluentialElectroacupuncture for Functional Constipation: A Multicenter, Randomized, Control Trial
Wu, X. W., Zheng, C., Xu, X., Ding, P., Xiong, F., Tian, M., Wang, Y., Dong, H., Zhang, M., Wang, W., et al. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/1428943 · Cited by 24
Tse, Y., Armstrong, D., Andrews, C. N., Bitton, A., Bressler, B. L., Marshall, J. K., & Liu, L. W. C. (2017) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2017/8612189 · Cited by 28
Medical Therapy of Constipation: Current Standards and Beyond
Andresen, V., & Layer, P. (2018) · Visceral Medicine · doi:10.1159/000488695 · Cited by 26
Placebo Response in Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis
Nee, J. W., Sugarman, M. A., Ballou, S., Katon, J. M., Rangan, V., Singh, P., Zubiago, J., Kaptchuk, T. J., & Lembo, A. J. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000399 · Cited by 24
Pennant, M. E., Orlando, R., Barton, P. M., Bayliss, S. E., Routh, K., & Meads, C. (2011) · Health Technology Assessment · doi:10.3310/hta15suppl1/05 · Cited by 23
Practical Treatments for Constipation in Korea
Park, K.-S., Choi, S. C., Park, M. I., Shin, J.-E., Jung, K. W., Kim, S., Lee, T.-H., Koo, H. S., & Constipation Study Group in the Korean Society of Neurogastroenterology and Motility (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.3.262 · Cited by 25
“Representative prokinetic drugs for constipation include 5-HT4 receptor agonists such as cisapride, tegaserod, and prucalopride [38-41].”
BackgroundKeller, J., Wedel, T., Seidl, H., Kreis, M. E., van der Voort, I., Gebhard, M., Langhorst, J., Jansen, P. L., Schwandner, O., Storr, M., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1646-1279 · Cited by 29
“[110] Camilleri M, Kerstens R, Rykx A et al.”
Irritable bowel syndrome; update on pathophysiology and management
Quigley, E. M. M., & Craig, O. F. (2012) · The Turkish Journal of Gastroenterology · doi:10.4318/tjg.2012.0551 · Cited by 24
“Three new 5-HT4 receptor agonists, prucalopride, AT-7505 and velusetrag (TD-5108) have been evaluated in clinical trials involving subjects with chronic constipation; three multi-centre studies have shown efficacy for prucalopride in constipation (123-125).”
BackgroundLiu, Z., Liu, J., Zhao, Y., Cai, Y., He, L., Xu, H., Zhou, X., Yan, S., Lao, L., & Liu, B. (2013) · Trials · doi:10.1186/1745-6215-14-176 · Cited by 24
“Weekly frequency of CSBMs is the primary endpoint, which is considered to be clinically meaningful since it combines a subjective measure of the completeness of evacuation with an objective measure of the number of bowel movements and reflects the relief of chronic constipation [3].”
BackgroundRefractory Constipation: What is the Clinician to Do?
Staller, K. D. (2018) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001049 · Cited by 25
Emerging Pharmacologic Therapies for Irritable Bowel Syndrome
Manabe, N., Rao, A. S., Wong, B. S., & Camilleri, M. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-010-0124-1 · Cited by 22
Self-citationEmerging drugs for chronic constipation
Crowell, M. D., Harris, L. A., Lunsford, T. N., & DiBaise, J. K. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903146890 · Cited by 25
“In addition, treatment with prucalopride was safe and well tolerated, although the side effect profile favored the 2 mg dose [38].”
BackgroundGale, J. D. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0027-4 · Cited by 21
Emerging Pharmacological Therapies for the Irritable Bowel Syndrome
Maneerattanaporn, M., Chang, L., & Chey, W. D. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.12.002 · Cited by 21
Anorektale Funktionsdiagnostik: Therapiealgorithmus bei Obstruktion und Inkontinenz
Kim, M., & Isbert, C. M. (2012) · Der Chirurg · doi:10.1007/s00104-012-2347-1 · Cited by 25
Effects of prucalopride on esophageal secondary peristalsis in humans
Yi, C., Lei, W., Hung, J., Liu, T., & Chen, C. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.58 · Cited by 21
“ademonstrated to be useful in the treatment of severe chronic constipation without significant side effects.(9,10)”
BackgroundChoopani, R., Ghourchian, A., Hajimehdipoor, H., Kamalinejad, M., & Ghourchian, F. (2017) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587217703018 · Cited by 24
Belgian consensus on irritable bowel syndrome
Kindt, S., Louis, H., Schepper, H. U. D., Arts, J., Caenepeel, P., Looze, D. A. D., Gerkens, A., Holvoet, T., Latour, P., Mahler, T., et al. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.10100 · Cited by 26
Treatment of gastrointestinal autonomic neuropathy
Törnblom, H. (2015) · Diabetologia · doi:10.1007/s00125-015-3828-9 · Cited by 21
Novel pharmacological therapies for irritable bowel syndrome
Corsetti, M., & Whorwell, P. J. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1158099 · Cited by 28
Delivery of care for functional gastrointestinal disorders: A systematic review
Basnayake, C., Kamm, M. A., Salzberg, M. R., Wilson-O'Brien, A. L., Stanley, A., & Thompson, A. J. V. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14830 · Cited by 23
Mozaffari, S., Nikfar, S., & Abdollahi, M. R. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759558 · Cited by 21
“The other novel agent is prucalopride, the selective ligand of 5-HT4 receptor with enterokinetic properties that has shown promising therapeutic effects in clinical trials [29,30].”
BackgroundUse acupuncture to treat functional constipation: study protocol for a randomized controlled trial
Li, Y., Zheng, H., Zeng, F., Zhou, S., Zhong, F., Zheng, H.-B., Chen, M., Jing, X., Cai, Y., Jia, B., et al. (2012) · Trials · doi:10.1186/1745-6215-13-104 · Cited by 20
“6 times between groups is considered to be of clinical relevance [16].”
BackgroundMethodFlach, S. D., Scarfe, G. B., Dragone, J., Ding, J., Seymour, M., Pennick, M., Pankratz, T., Troy, S. M., & Getsy, J. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.08.003 · Cited by 23
Emmett, C., Close, H. J., Mason, J. M., Taheri, S., Stevens, N. J., Eldridge, S. M., Norton, C. S., Knowles, C. H., & Yiannakou, Y. (2017) · Trials · doi:10.1186/s13063-017-1882-y · Cited by 20
McKinnell, R. M., Armstrong, S. R., Beattie, D. T., Fatheree, P. R., Long, D. D., Marquess, D. G., Shaw, J., & Vickery, R. G. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.018 · Cited by 20
Woitalla, D., & Goetze, O. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.06.050 · Cited by 22
“Modulation of GI-motility by 5-HT4-agonists [82,96-99].”
Pharmakologische Behandlung der Obstipation
Müller-Lissner, S. A. (2013) · Der Internist · doi:10.1007/s00108-013-3245-4 · Cited by 19
Guidelines for the Treatment of Constipation
Park, M. I., Shin, J. E., Myung, S., Huh, K. C., Choi, C. H., Jung, S.-A., Choi, S. C., Sohn, C.-I., Choi, M., & The Korean Society of Neurogastroenterology and Motility (2011) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2011.57.2.100 · Cited by 20
“12주 동안 620명의 심한 만성 변비 환자에게 2 mg, 4 mg을 각각 투여한 군과 대조군을 비교하였으며, 약제 투여군에서 대조군에 비해 주당 1회 이상 의 완전 자발적 배변의 빈도가 증가하였다.(95) 다른 연구에서도 713명의 만성 변비 환자에게 prucalopride 2 mg과 4 mg을”
BackgroundConsenso mexicano sobre estreñimiento crónico
Remes-Troche, J. M., Coss‐Adame, E., López‐Colombo, A., Amieva‐Balmori, M., Sánchez, R. C., Guindic, L. C., Rendón, R. F., Escudero, O. G., Martínez, M. G., Chávez, M. E. I., et al. (2018) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2017.12.005 · Cited by 25
Staller, K. D., Hinson, J., Kerstens, R., Spalding, W. M., & Lembo, A. J. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001521 · Cited by 20
“gov identifiers: NCT00488137 (6), NCT00483886 (7), NCT00485940 (8), NCT01147926 (9), NCT01116206 (10), and NCT01424228 (11)).”
Self-citationXue, Q., Li, N., Liu, Z., Wang, C., & Lu, J. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-2044-2 · Cited by 21
“The main secondary effi cacy end point was CSS assessed patients' constipation symptoms at baseline and at week 1, 2, 3 and 4.((22)) About eight constipationrelated symptoms were recorded and scored by patients, including straining, endless sensation of defecation, stool consistency, bowel sound, abdominal pain, abdom…”
BackgroundPrucalopride in intestinal pseudo obstruction, paediatric experience and systematic review
Mutalib, M., Kammermeier, J., Vora, R., & Borrelli, O. (2021) · Acta gastro-enterologica belgica · doi:10.51821/84.3.002 · Cited by 18
Transanale Verfahren bei funktionellen Darmerkrankungen
Isbert, C. M., & Germer, C.-T. (2012) · Der Chirurg · doi:10.1007/s00104-012-2350-6 · Cited by 18
Novel diagnostics and therapy of colonic motor disorders
Dinning, P. G., & Scott, S. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.002 · Cited by 18
Perspective on Physical Therapist Management of Functional Constipation
George, S. E., & Borello‐France, D. (2016) · Physical Therapy · doi:10.2522/ptj.20160110 · Cited by 20
Sildenafil normalizes bowel transit in preclinical models of constipation
Sharman, S. K., Islam, B. N., Hou, Y., Usry, M., Bridges, A. E., Singh, N., Sridhar, S., Rao, S. S. C., & Browning, D. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176673 · Cited by 19
Zhou, J., Liu, Y., Zhou, K., Liu, B., Su, T., Wang, W., & Liu, Z. (2019) · BioMed Research International · doi:10.1155/2019/7491281 · Cited by 18
Patient-Reported Outcome After Ostomy Surgery for Chronic Constipation
Iqbal, F., van der Ploeg, V. A., Adaba, F., Askari, A., Murphy, J., Nicholls, R. J., & Vaizey, C. J. (2018) · Journal of Wound Ostomy and Continence Nursing · doi:10.1097/won.0000000000000445 · Cited by 18
Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders
Sanger, G. J., Chang, L., Bountra, C., & Houghton, L. A. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10369922 · Cited by 17
“…(COMT) [Tahara et al. 2008], a-adrenergic 2A and 2C receptors [Kim et al. 2004], G-protein coupled receptors, [Grudell et al. 2008; Camilleri et al. 2008c; Saito et al. 2007; Holtmann et al. 2004], neuropeptide S receptor 1 [Camilleri et al. 2010], enzymes involved in…”
BackgroundMethodInfluentialRole of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review
Ali, H., Pamarthy, R., & Sarfraz, S. (2021) · Cureus · doi:10.7759/cureus.14306 · Cited by 20
“[21] 12 weeks Multicenter, randomized, placebocontrolled, parallel-group study 620 30.”
Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach
Kaniecki, T., Hughes, M., & McMahan, Z. H. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2320205 · Cited by 18
“Prucalopride is a more specific 5-HT4 receptor agonist without the cardiotoxicity profile, with several large general population studies [153,154] showing efficacy in chronic constipation treatment.”
BackgroundDaniali, M., Nikfar, S., & Abdollahi, M. R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1668927 · Cited by 17
ONS Guidelines™ for Opioid-Induced and Non–Opioid-Related Cancer Constipation
Rogers, B. B., Ginex, P., Anbari, A. B., Hanson, B., LeFebvre, K. B., Lopez, R., Thorpe, D. M., Wolles, B., Moriarty, K., Maloney, C., et al. (2020) · Oncology nursing forum · doi:10.1188/20.onf.671-691 · Cited by 18
Patel, S. N., Doerfler, B., Boutros, K., Ng, S., Manuel, M., & DeSimone, E. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s274568 · Cited by 20
Parker, M., Haycox, A. R., & Graves, J. (2011) · PharmacoEconomics · doi:10.2165/11588360-000000000-00000 · Cited by 17
“In undertaking this study, the analysis benefited from access to the large quantity of QOL data derived from the clinical trials undertaken for a new drug (prucalopride) for the treatment of severe chronic constipation.([6-8]) As in most clinical trials, outcome measures were identified in two dimensions: (i) ‘physica…”
MethodAndresen, V., Pehl, C., Allescher, H. ‐., Bischoff, S. C., Enck, P., Frieling, T., Haag, S., Holtmann, G., Karaus, M., Keller, J., et al. (2011) · Cited by 17
Conlon, K. M., Maeyer, J. H. D., Bruce, C., Schuurkes, J. A. J., Christie, L., McRedmond, J. P., Derakhchan, K., & Wade, P. R. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244079 · Cited by 17
“The efficacy of prucalopride in increasing the frequency of bowel movements and improving patient-reported symptoms and quality of life has been demonstrated in a series of phase III trials (Camilleri et al., 2008; Quigley et al., 2009; Tack et al., 2009; Yiannakou et al., 2015).”
BackgroundPsychopharmacologic Therapies for Irritable Bowel Syndrome
Törnblom, H., & Drossman, D. A. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.04.005 · Cited by 19
Management of constipation in the elderly: Emerging therapeutic strategies
Kapoor, S. N. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5226 · Cited by 17
“In fact, Camilleri et al in a recent study reported that the average number of bowel movements increased by at least one in nearly 47% of the patients who were administered a dose of 4 mg [ 2 ]”
BackgroundTreating Constipation With Prucalopride: One Size Does Not Fit All
Nurko, S., & Saps, M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.024 · Cited by 17
Hamatani, T., Fukudo, S., Nakada, Y., Inada, H., Kazumori, K., & Miwa, H. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15907 · Cited by 16
Advancing treatment options for chronic idiopathic constipation
Quigley, E. M. M., & Neshatian, L. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1127356 · Cited by 19
Prucalopride: A Review in Chronic Idiopathic Constipation
Garnock-Jones, K. P. (2015) · Drugs · doi:10.1007/s40265-015-0518-3 · Cited by 17
“medication [33–39] and had at least one post-baseline efficacy assessment [34, 36, 37]; one study [33] excluded patients from a site where a serious breach in good clinical practice was identified.”
BackgroundInfluentialTack, J. F., Boardman, H., Layer, P., Schiefke, I., Jayne, D. G., Scarpignato, C., Fox, M., Frieling, T., Ducrotte, P. R., Hamdy, S., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13874 · Cited by 16
New Options in Constipation Management
Davis, M. P., & Gamier, P. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0481-x · Cited by 17
Tan, S., Zhang, W., Zeng, P., Yang, Y., Chen, S., Li, Y., Bian, Y., & Chen, X. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002786 · Cited by 16
New pharmacological treatment options for chronic constipation
Corsetti, M., & Tack, J. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.900543 · Cited by 15
“More than 80% of these reported that they failed to be adequately relieved by preceding laxative treatments [26-28].”
BackgroundVitton, V., Benezech, A., Honoré, S., Sudour, P., Lesavre, N., Auquier, P., & Baumstarck, K. (2015) · Trials · doi:10.1186/s13063-015-0752-8 · Cited by 15
“The primary endpoint was chosen considering the last randomized trial on severe chronic constipation published in the New England Journal of Medicine [9].”
InfluentialThe Effects of Prucalopride on Postoperative Ileus in Guinea Pigs
Park, S. J., Choi, E. J., Yoon, Y. H., & Park, H. (2013) · Yonsei Medical Journal · doi:10.3349/ymj.2013.54.4.845 · Cited by 15
Lu, P. L., & Mousa, H. M. (2018) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2018.07.009 · Cited by 15
Knowles, C. H., Booth, L., Brown, S. R., Cross, S., Eldridge, S. M., Emmett, C., Grossi, U., Jordan, M., Lacy‐Colson, J., Mason, J. M., et al. (2021) · Programme Grants for Applied Research · doi:10.3310/pgfar09140 · Cited by 15
Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers
Chen, X., Jiang, J., Liu, T., Liu, H., Zhong, W., & Hu, P. (2012) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201769 · Cited by 15
Leelakusolvong, S., Ke, M., Zou, D., Choi, S. C., Tack, J. F., Quigley, E. M. M., Liu, A., & Kim, J. (2014) · Gut and Liver · doi:10.5009/gnl14290 · Cited by 15
“In this study, the results of an integrated analysis of the pooled data from four phase III studies are reported.(14,16,18,20) An additional analysis was performed to evaluate the association of baseline factors with the most frequently reported TEAEs across the subgroups.”
MethodYang, X., Liu, Y., Liu, B., He, L., Liu, Z., Yan, Y., Liu, J., & Liu, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187723 · Cited by 15
Constipation, IBs and the 5-HT 4 Receptor: What Role for Prucalopride?
Sanger, G. J., & Quigley, E. M. M. (2010) · Clinical Medicine Insights Gastroenterology · doi:10.4137/cgast.s4136 · Cited by 15
Camilleri, M. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11401773 · Cited by 16
“Thus, the estimated number needed to treat for prucalopride and linaclotide may be better than those reported for the endpoints of more than three spontaneous complete bowel movements (approximately seven) and more than three spontaneous bowel movements (approximately four) [Lembo et al. 2010; Quigley et al. 2009; Tac…”
BackgroundSelf-citationMahajan, R. (2019) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_412_18 · Cited by 15
Nardo, G. D., Zenzeri, L., Guarino, M., Molfino, A., Parisi, P., Barbara, G., Stanghellini, V., & GIORGIO, R. D. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2193887 · Cited by 14
Patient-Reported Outcomes in Disorders of Gut–Brain Interaction
Tack, J. F., Carbone, F., Chang, L., & Lacy, B. E. (2024) · Gastroenterology · doi:10.1053/j.gastro.2023.11.307 · Cited by 16
Effect of Prucalopride on the Pharmacokinetics of Oral Contraceptives in Healthy Women
de Velde, V. V., Vandeplassche, L. M., Hoppenbrouwers, M., Boterman, M., & Ausma, J. (2013) · Drugs in R&D · doi:10.1007/s40268-013-0008-6 · Cited by 14
“Across the pivotal trials, the most frequently reported AEs associated with therapy were headache (25 % of patients) and gastrointestinal symptoms (nausea [19 %], diarrhea [12 %], or abdominal pain [12 %]) [3, 4].”
BackgroundResultInfluentialSelf-citationTreatment for constipation: New and old pharmacological strategies
Lacy, B. E., Hussain, Z. H., & Mearin, F. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12335 · Cited by 17
Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.
Hussain, Z. H., Everhart, K. K., & Lacy, B. E. (2015) · PubMed · Cited by 15
Zhang, T., Wang, G., Li, B., Wang, L., Guo, J., Hu, J., Du, X., Hong, Q.-Y., Sun, J.-Q., & Liu, C. (2018) · Trials · doi:10.1186/s13063-018-2750-0 · Cited by 14
Mearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2017) · Atención Primaria · doi:10.1016/j.aprim.2017.01.003 · Cited by 20
Lee, M. J. (2014) · International Journal of Gastroenterology Disorders & Therapy · doi:10.15344/2393-8498/2014/108 · Cited by 13
“In phase III clinical trials for 12 weeks in patients with chronic idiopathic constipation (> 1977 patients) [85-87] , the patients treated with prucalopride reported a statistically significant (p<0.”
Long‐term outcome of prucalopride for chronic constipation: a single‐centre study
Rao, P. K. D., Lewis, M., Peiris, S. P. M., Shah, P. R., & Haray, P. N. (2015) · Colorectal Disease · doi:10.1111/codi.12993 · Cited by 13
Metadata
- Authors
- Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Camilleri, Michael
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-29
- Volume
- 358
- Issue
- 22
- Pages
- 2344-2354
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068454300
- Cited by
- 576
- References
- 36
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 28 · 2020: 28 · 2019: 19 · 2018: 29 · 2017: 33 · 2016: 38 · 2015: 33 · 2014: 46 · 2013: 50 · 2012: 49
- FWCI
- 45.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- prucalopride, serotonin receptor agonists, 5-HT4 receptor agonist, stool frequency, treatment-related adverse events, cardiovascular safety
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Benzofurans, Chronic Disease, Constipation, Defecation, Double-Blind Method, Electrocardiography, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Serotonin Receptor Agonists, Laxatives, Serotonin 5-HT4 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.